Show simple item record

dc.contributor.authorChrisanthar, Ranjan
dc.contributor.authorKnappskog, Stian
dc.contributor.authorLøkkevik, Erik
dc.contributor.authorAnker, Gun
dc.contributor.authorØstenstad, Bjørn
dc.contributor.authorLundgren, Steinar
dc.contributor.authorBerge, Elisabet O.
dc.contributor.authorRisberg, Terje
dc.contributor.authorMjaaland, Ingvil
dc.contributor.authorMæhle, Lovise
dc.contributor.authorEngebretsen, Lars Fredrik
dc.contributor.authorLillehaug, Johan Richard
dc.contributor.authorLønning, Per Eystein
dc.date.accessioned2011-05-05T08:11:42Z
dc.date.available2011-05-05T08:11:42Z
dc.date.issued2008-08-26
dc.description.abstractBackground Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis or global gene expression profiles have failed to identify mechanisms causing in vivo resistance to anthracyclines. While we previously found TP53 mutations in the L2/L3 domains to be associated with drug resistance, some tumors harboring wild-type TP53 were also therapy resistant. The aim of this study was; 1) To explore alterations in the TP53 gene with respect to resistance to a regular dose epirubicin regimen (90 mg/m2 every 3 week) in patients with primary, locally advanced breast cancer; 2) Identify critical mechanisms activating p53 in response to DNA damage in breast cancer; 3) Evaluate in vitro function of Chk2 and p14 proteins corresponding to identified mutations in the CHEK2 and p14(ARF) genes; and 4) Explore potential CHEK2 or p14(ARF) germline mutations with respect to family cancer incidence. <p>Methods and Findings Snap-frozen biopsies from 109 patients collected prior to epirubicin (as preoperative therapy were investigated for TP53, CHEK2 and p14(ARF) mutations by sequencing the coding region and p14(ARF) promoter methylations. TP53 mutastions were associated with chemoresistance, defined as progressive disease on therapy (p = 0.0358; p = 0.0136 for mutations affecting p53 loop domains L2/L3). Germline CHEK2 mutations (n = 3) were associated with therapy resistance (p = 0.0226). Combined, mutations affecting either CHEK2 or TP53 strongly predicted therapy resistance (p = 0.0101; TP53 mutations restricted to the L2/L3 domains: p = 0.0032). Two patients progressing on therapy harbored the CHEK2 mutation, Arg95Ter, completely abrogating Chk2 protein dimerization and kinase activity. One patient (Epi132) revealed family cancer occurrence resembling families harboring CHEK2 mutations in general, the other patient (epi203) was non-conclusive. No mutation or promoter hypermethylation in p14(ARF) were detected. <p>Conclusion This study is the first reporting an association between CHEK2 mutations and therapy resistance in human cancers and to document mutations in two genes acting direct up / down-stream to each other to cause therapy failure, emphasizing the need to investigate functional cascades in future studies.en
dc.identifier.citationPLoS ONE 3(2008) nr. 8 s. 3062-3079en
dc.identifier.cristinIDFRIDAID 359552
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/10037/3276
dc.identifier.urnURN:NBN:no-uit_munin_3007
dc.language.isoengen
dc.publisherPublic Library of Science (PLoS)en
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en
dc.titleCHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Canceren
dc.typeJournal articleen
dc.typeTidsskriftartikkelen
dc.typePeer revieweden


File(s) in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record